Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial - Archive ouverte HAL Access content directly
Journal Articles Haematologica Year : 2015

Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial

P. Rodon
  • Function : Author
C. Hulin
  • Function : Author
B. Pegourie
  • Function : Author
M. Tiab
  • Function : Author
B. Anglaret
  • Function : Author
L. Benboubker
  • Function : Author
B. Kolb
  • Function : Author
L. Garderet
  • Function : Author
X. Leleu
  • Function : Author
O. Fitoussi
  • Function : Author
C. Chaleteix
  • Function : Author
P. Lenain
  • Function : Author
B. Royer
  • Function : Author
Arnaud Banos
R. Benramdane
  • Function : Author
P. Cony-Makhoul
  • Function : Author
M. Dib
  • Function : Author
J. Fontan
  • Function : Author
M.-O. Petillon
  • Function : Author

Dates and versions

hal-01116536 , version 1 (13-02-2015)

Identifiers

Cite

P. Rodon, C. Hulin, B. Pegourie, M. Tiab, B. Anglaret, et al.. Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial. Haematologica, 2015, 100 (2), pp.e56-9. ⟨10.3324/haematol.2014.110890⟩. ⟨hal-01116536⟩
295 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More